MIR6889

Across TCGA pan-cancer cohorts, MIR6889 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MIR6889’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where MIR6889 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR6889 is over-expressed in tumor.

STAD, CHOL, and COAD are the cancer types where MIR6889 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIR6889 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	II,III,IV	+0.480	.004	5	view →
CHOL	All	All	+1.165	.002	3	view →
COAD	Male	II,III,IV	+0.371	.007	3	view →
LUAD	Female	All	+0.268	.019	2	view →
HNSC	Male	All	+0.193	.028	2	view →
LUSC	Male	All	+0.290	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MIR6889–STAD

Open the STAD breakdown →